medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2024, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2024; 22 (4)

Cutaneous leishmaniasis, an unusual clinical presentation

Quijada UZM, Quijada UEE

Language: Spanish
References: 12
Page: 336-339
PDF size: 200.79 Kb.


ABSTRACT

Cutaneous leishmaniasis is a chronic condition caused by a protozoan parasite of the genus Leishmania. The disease is transmitted to humans through the bite of female sandflies. The World Health Organization (WHO) classifies cutaneous leishmaniasis as an emerging, uncontrolled and a neglected tropical disease.
We report a 28-year-old man, with a localized dermatosis on the left forearm with an erythematous scaly plaque measuring 14 × 8 cm, with defined borders. The patient received treatment with meglumine antimoniate, with clinical improvement.
It’s relevant to consider that the presence of a large cutaneous leishmaniasis plaque could mimic other cutaneous disorders.


REFERENCES

  1. Bailey F, Mondragón-Shem K, Hotez P, Ruiz-Postigo JA et al., Anew perspective on cutaneous leishmaniasis: implications forglobal prevalence and burden of disease estimates, plos NeglectedTropical Diseases 2017; 11(8):e0005739. Disponible en:https://doi.org/10.1371/journal.pntd.0005739.

  2. De Vries HJC y Schallig HD, Cutaneous leishmaniasis: a 2022updated narrative review into diagnosis and management developments,American Journal of Clinical Dermatology 2022;23(6):823-40. Disponible en: https://doi.org/10.1007/s40257-022-00726-8.

  3. Ruiz-Postigo JA. Jain S, Mikhailov A y Nilce A, Global leishmaniasissurveillance: 2019-2020, a baseline for the 2030 roadmap,Ginebra, World Health Organization, 2020. Disponible en:https://iris.who.int/bitstream/handle/10665/344795/WER9635-

  4. 401-419-eng-fre.pdf?sequence=1.4. Pérez I, Durán E, Pérez F, Trueba M y Mendizábal-Cabrera R, Documentode política: recomendaciones para el fortalecimientodel control de la leishmaniasis cutánea en Guatemala (versión 1),Universidad de Sussex, 2020. Disponible en: https://hdl.handle.net/10779/uos.23308145.v1.

  5. Leishmaniasis. Informe Epidemiológico de las Américas, diciembrede 2019, Informe de leishmaniasis, 8. Disponible en:https://iris.paho.org/handle/10665.2/51739.

  6. Iddawela D, Vithana SMP, Atapattu D y Wijekoon L, Clinical andepidemiological characteristics of cutaneous leishmaniasis inSri Lanka, bmc Infectious Diseases 2018; 18(1). Disponible en:https://doi.org/10.1186/s12879-018-2999-7.

  7. Maxfield L y Crane JS, Leishmaniasis, StatPearls Publishing,2023. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK531456/.

  8. Leishmaniasis, 2019, Cdc.gov. Disponible en: https://www.cdc.gov/dpdx/leishmaniasis/index.html.

  9. Aronson N, Herwaldt BL, Libman M, Pearson R, et al., Diagnosisand treatment of leishmaniasis: clinical practice guidelinesby the infectious diseases society of America (idsa) andthe American Society of Tropical Medicine and Hygiene (astmh),The American Journal of Tropical Medicine and Hygiene2017; 96(1), 24-45. Disponible en: https://doi.org/10.4269/ajtmh.16-84256.

  10. Pan American Health Organization, Guideline for the treatmentof leishmaniasis in the Americas, Pan American Health Organization,2ª ed., 2022. Disponible en: https://doi.org/10.37774/9789275125038.

  11. Garza-Tovar TF, Sacriste-Hernández MI, Juárez-Durán ER yArenas R, An overview of the treatment of cutaneous leishmaniasis,Faculty Reviews 2020; 9. Disponible en: https://doi.org/10.12703/r/9-28.

  12. Organización Panamericana de la Salud, Síntesis de evidenciay recomendaciones: directrices para el tratamiento de las leishmaniasisen la Región de las Américas, Revista Panamericanade Salud Pública 2023; 47, 1. Disponible en: https://doi.org/10.26633/rpsp.2023.43.




2020     |     www.medigraphic.com